Search CHRS
Coherus Oncology, Inc.
Nasdaq · CIK 1512762
Last close1.16
Daily change+0.00 (0.00%)
10 Years gain-95.44%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CHRS · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
28.9Momentum
n/aAcceleration
n/aConfidence
62.0Annual Revenue7
Quarterly Revenue30
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTMn/aINSUFFICIENT_HISTORY
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin95.2%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $28.36M | -$181.13M | -$138.51M | n/a | n/a | n/a | n/a | n/a | 117.14M |
| 2025 FY Dec 31, 2024 | n/a | $17.66M | -$199.65M | -$20.44M | n/a | n/a | n/a | n/a | n/a | 114.55M |
| 2024 FY Dec 31, 2023 | n/a | $98.25M | -$203.20M | -$174.88M | n/a | n/a | n/a | n/a | n/a | 94.16M |
| 2024 FY Dec 31, 2022 | n/a | $140.96M | -$256.88M | -$241.12M | n/a | n/a | n/a | n/a | n/a | 77.63M |
| 2023 FY Dec 31, 2021 | n/a | $268.96M | -$263.86M | -$37.43M | -$38.72M | n/a | n/a | n/a | n/a | 75.45M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $356.07M | sum latest 4 fiscal quarters Revenue | OK | 0001564590-20-007416 |
| Revenue Growth TTM | n/a | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | INSUFFICIENT_HISTORY | 0001564590-20-007416 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001564590-19-005470 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001564590-19-005470 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 95.2% | Gross Profit / Revenue | OK | 0001564590-20-007416 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001558370-20-005749, 0001558370-21-015033 |
| Current Ratio | 2.98x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 2.41x | (Cash + Short-term Investments) / Total Debt | OK | 0001558370-21-015033 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | derived |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |